‘You have to get up on the podi­um’: In­com­ing BIO chair Paul Hast­ings on di­ver­si­ty, drug pric­ing and work­ing with the FDA

Paul Hast­ings’ day job as CEO of Nkar­ta has him talk­ing about nat­ur­al killer cells and their po­ten­tial ap­pli­ca­tions in can­cer. But through­out the pan­dem­ic you’ll like­ly re­mem­ber him in his oth­er role: As vice chair of BIO, the biotech trade group, he would of­ten sign his name right un­der chair­man (and Ovid CEO) Je­re­my Levin, call­ing for FDA in­de­pen­dence, stand­ing up for the right to vote, and en­cour­ag­ing oth­ers to speak out.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN